Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.33 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.31 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.32 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.32 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL2035907 | 0.96 | KCNA4 (0.32) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL31512473 | 0.79 | CA1 (0.37) | CA1CA4 | |
| SCHEMBL16857488 | 0.79 | CA1 (0.37) | CA1CA4 | |
| SCHEMBL1829037 | 0.77 | FFAR3 (0.35) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL877771 | 0.77 | FFAR3 (0.35) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL2035911 | 0.76 | FFAR3 (0.33) | — | |
| SCHEMBL10400494 | 0.72 | NPSR1 (0.31) | — | |
| SCHEMBL16466884 | 0.71 | — | — | |
| SCHEMBL2658696 | 0.68 | — | — | |
| SCHEMBL17801156 | 0.68 | USP2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186854-B2 | Process for making bicalutamide and intermediates thereof | SYNTHON IP INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1546093-A1 | PROCESS FOR MAKING BICALUTAMIDE AND INTERMEDIATES THEREOF | Synthon B.V. (NL) | 2005-06-29 | — | — | EP | disclosed |
| US-6818766-B2 | USING P-FLUOROBENZENESULFINIC ACID | SYNTHON BV (NL) | 2004-11-16 | — | — | US | disclosed |
| WO-2004031136-A1 | PROCESS FOR MAKING BICALUTAMIDE AND INTERMEDIATES THEREOF | SYNTHON B.V. (NL) | 2004-04-15 | — | — | WO | disclosed |
| US-20040068135-A1 | Process for making bicalutamide and intermediates thereof | SYNTHON IP INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030073742-A1 | Process for making bicalutamide and intermediates thereof | SYNTHON B.V. (NL) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073742-A1 | Process for making bicalutamide and intermediates thereof | BLVRB, BRDT, OTUB1 | CA1 251/4885CA4 318/4885KCNA4 1980/4885 |
| US-20040068135-A1 | Process for making bicalutamide and intermediates thereof | BLVRB, BRDT, OTUB1 | CA1 251/4885CA4 318/4885KCNA4 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.